Jubilant Clinsys Inc.
Balance Sheet as at 31 March 2026
(All amounts in USD, unless otherwise stated)

	Notes	As at 31 March 2026	As at 31 March 2025
ASSETS			
Non-current assets			
Property, plant and equipment	3	-	-
Total non-current assets		**-**	**-**
Current assets			
Financial assets			
i. Cash and cash equivalents	4	53,675	50,901
Total current assets		**53,675**	**50,901**
Total assets		**53,675**	**50,901**
EQUITY AND LIABILITIES			
Equity			
Equity share capital	5	38,725,630	38,725,630
Other equity		(38,736,566)	(38,735,707)
Total equity		**(10,936)**	**(10,077)**
Liabilities			
Current liabilities			
Financial liabilities			
i. Trade payables	7	46,199	42,566
Current tax liabilities (net)		18,412	18,412
Total current liabilities		**64,611**	**60,978**
Total liabilities		**64,611**	**60,978**
Total equity and liabilities		**53,675**	**50,901**

For **Jubilant Clinsys Inc.**

Mr. Krishna Kumar Khaitan
Director
Date: 13 May 2026

Jubilant Clinsys Inc.
Statement of Profit and Loss for the year ended 31 March 2026
(All amounts in USD, unless otherwise stated)

	Notes	For the year ended 31 March 2026	For the year ended 31 March 2025
Other income	8	3,657	-
Total income		**3,657**	**-**
Expenses			
Other expenses	9	2,985	2,635
Total expenses		**2,985**	**2,635**
Profit/loss before tax		**672**	**(2,635)**
Tax expense			
- Current tax		1,531	1,556
Total tax expense		**1,531**	**1,556**
Loss for the year		**(859)**	**(4,191)**
Other comprehensive income for the year, net of tax		**-**	**-**
Total comprehensive loss for the year		**(859)**	**(4,191)**

Jubilant Clinsys Inc.
Statement of Changes in Equity for the year ended 31 March 2026
(All amounts in USD, unless otherwise stated)

A. Equity share capital	Amount
Balance as at 1 April 2024	**38,725,630**
Changes in equity share capital during the year (refer note 5)	-
Balance as at 31 March 2025	**38,725,630**
Changes in equity share capital during the year	-
Balance as at 31 March 2026	**38,725,630**

B. Other equity

	Reserves and surplus		Total
	Capital reserve	Retained earnings	
Balance as at 1 April 2024	**5,373**	**(38,736,889)**	**(38,731,516)**
Loss for the year	-	(4,191)	(4,191)
Other comprehensive income	-	-	-
Total comprehensive loss for the year	**-**	**(4,191)**	**(4,191)**
Balance as at 31 March 2025	**5,373**	**(38,741,080)**	**(38,735,707)**
Loss for the year	-	(859)	(859)
Other comprehensive income	-	-	-
Total comprehensive loss for the year	**-**	**(859)**	**(859)**
Balance as at 31 March 2026	**5,373**	**(38,741,939)**	**(38,736,566)**

Jubilant Clinsys Inc.
Statement of Cash Flows for the year ended 31 March 2026
(All amounts in USD, unless otherwise stated)

	As at 31 March 2026	As at 31 March 2025
A. Cash flow from operating activities		
Net Profit/loss before tax	672	(2,635)
Adjustments	-	-
	-	**-**
Operating cash flow before working capital changes	**672**	**(2,635)**
Increase in trade payables, other financial liabilities, other liabilities and provisions	2,102	-
Cash generated from/used in operations	**2,774**	**(2,635)**
Income tax paid (net of refund)	-	-
Net cash generated from/used in operating activities	**2,774**	**(2,635)**
B. Cash flow from investing activities	-	-
C. Cash flow from financing activities	-	-
Net increase/decrease in cash and cash equivalents (A+B+C)	**2,774**	**(2,635)**
Cash and cash equivalents at the beginning of year	50,901	53,536
Cash and cash equivalents at the end of the year	**53,675**	**50,901**

Note 1: Corporate information

Jubilant Clinsys Inc. (“the Company”) was incorporated in United States of America (“USA”) on May 11, 1992. The Company is a wholly owned subsidiary of Jubilant Pharma Holdings Inc., a Delaware Corporation (“the holding company”) whose ultimate parent company is Jubilant Pharmova Limited, a company incorporated in India. The Company was primarily engaged in monitoring of clinical trials for pharmaceutical companies in the USA.

Note 2. Material accounting policies

This note provides a list of the material accounting policies adopted in the preparation of these financial statements. The accounting policies adopted are consistent with those of the previous financial year.

(a) Basis of preparation

(i) Statement of compliance

These financial statements with limited information have been prepared solely for consideration in the consolidated financial statements of the Ultimate Parent Company. These financial statements have been prepared in accordance with the Ultimate Parent's accounting policies which are in agreement with the recognition and measurement principles laid down under the Companies (Indian Accounting Standards) Rules, 2015, as amended.

(ii) Historical cost convention

These financial statements have been prepared under historical cost convention on accrual basis, unless otherwise stated.

(b) Functional and presentation currency

Items included in the financial statements of the Company are measured using the currency of the primary economic environment in which the entity operates (i.e. the "functional currency"). The functional currency of the Company is U.S. Dollars (“USD”). These financial statements are presented in USD.

(c) Current versus non-current classification

The Company presents assets and liabilities in the Balance Sheet based on current/non-current classification.
An asset is treated as current when:

- It is expected to be realised or intended to be sold or consumed in normal operating cycle;
- It is held primarily for the purpose of trading;
- It is expected to be realised within twelve months after the reporting period; or
- It is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

The Company classifies all other assets as non-current.

A liability is current when:

- It is expected to be settled in normal operating cycle;
- It is held primarily for the purpose of trading;
- It is due to be settled within twelve months after the reporting period; or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.

The Company classifies all other liabilities as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities respectively.

The operating cycle is the time between the acquisition of assets for processing and their realisation in cash and cash equivalents. The Company has identified twelve months as its operating cycle for the purpose of current-non-current classification of assets and liabilities.

Jubilant Clinsys Inc.
Notes to the financial statements for the year ended 31 March 2026
(All amounts in USD, unless otherwise stated)

Note 3: Property, plant and equipment

Description	**Furniture and fixtures**	**Office equipment**	**Total**
Gross carrying amount as at 1 April 2024	**1,782**	**2,524**	**4,306**
Additions	-	-	-
Gross carrying amount as at 31 March 2025	**1,782**	**2,524**	**4,306**
Accumulated depreciation as at 1 April 2024	**1,782**	**2,524**	**4,306**
Depreciation charge for the year	-	-	-
Accumulated depreciation as at 31 March 2025	**1,782**	**2,524**	**4,306**
Net carrying amount as at 31 March 2025	**-**	**-**	**-**

Description	**Furniture and fixtures**	**Office equipment**	**Total**
Gross carrying amount as at 1 April 2025	**1,782**	**2,524**	**4,306**
Additions	-	-	-
Gross carrying amount as at 31 March 2026	**1,782**	**2,524**	**4,306**
Accumulated depreciation as at 1 April 2025	**1,782**	**2,524**	**4,306**
Depreciation charge for the year	-	-	-
Accumulated depreciation as at 31 March 2026	**1,782**	**2,524**	**4,306**
Net carrying amount as at 31 March 2026	**-**	**-**	**-**

Note 4: Cash and cash equivalents

	As at 31 March 2026	As at 31 March 2025
Balances with banks		
- in current accounts	53,675	50,901
Total cash and cash equivalents	**53,675**	**50,901**

Note 5: Equity share capital

	As at 31 March 2026	As at 31 March 2025
Authorised		
45,000,000 (31 March 2025: 45,000,000) Common stock of no par value	-	-
	-	**-**
Issued and subscribed		
40,562,584 (31 March 2025: 40,562,584) Common stock of no par value	38,725,630	38,725,630
	38,725,630	**38,725,630**

Movement in equity share capital	**No. of shares**	**Amount**
As at 1 April 2024	40,562,584	38,725,630
Additions during the year	-	-
As at 31 March 2025	40,562,584	38,725,630
Additions during the year	-	-
As at 31 March 2026	40,562,584	38,725,630

Terms and rights attached to equity shares

The Company has only one class of Common stock referred to herein as equity shares. Each holder of common stock is entitled to one vote per common stock. In the event of liquidation of the Company, the stockholders shall be entitled to receive all of the remaining assets of the Company, after distribution of all preferential amounts, if any. Such amounts will be in proportion to the number of common stock of equity shares held by the stockholders.

Details of shareholders holding more than 5% shares in the Company:

	As at 31 March 2026		As at 31 March 2025	
	No. of shares	**% holding**	**No. of shares**	**% holding**
Jubilant Pharma Holdings Inc., USA - the holding company Common stock of no par value	40,562,584	100.00%	40,562,584	100.00%

Note 6: Nature and purpose of other equity

Capital reserve

Accumulated capital surplus not available for distribution of dividend and expected to remain invested permanently. This also includes reserves arising on transaction with owners of the Company.

Retained earnings

Retained earnings represent the amount of accumulated earnings/(loss) of the Company.

Note 7: Trade payables

	As at 31 March 2026	As at 31 March 2025
Current		
Dues to relates parties	24,850	22,316
Dues to others	21,349	20,250
Total trade payables	**46,199**	**42,566**

Note 8: Other income

	For the year ended 31 March 2026	For the year ended 31 March 2025
Net foreign exchange income	3,657	-
Total other income	**3,657**	**-**

Note 9: Other expenses

	For the year ended 31 March 2025	For the year ended 31 March 2024
Legal and professional fees	2,102	-
Bank charges	883	2,327
Net foreign exchange loss	-	308
Total other expenses	**2,985**	**2,635**